nodes	percent_of_prediction	percent_of_DWPC	metapath
Asenapine—HRH2—gastric juice—esophageal cancer	0.0786	0.353	CbGeAlD
Asenapine—HTR7—vagus nerve—esophageal cancer	0.0215	0.0965	CbGeAlD
Asenapine—HTR2A—vagus nerve—esophageal cancer	0.0134	0.0602	CbGeAlD
Asenapine—Hypoaesthesia oral—Capecitabine—esophageal cancer	0.0093	0.0398	CcSEcCtD
Asenapine—Localized exfoliation—Capecitabine—esophageal cancer	0.00901	0.0385	CcSEcCtD
Asenapine—UGT1A4—digestive system—esophageal cancer	0.00764	0.0343	CbGeAlD
Asenapine—Sinus tachycardia—Capecitabine—esophageal cancer	0.00603	0.0258	CcSEcCtD
Asenapine—Paraesthesia oral—Capecitabine—esophageal cancer	0.00518	0.0221	CcSEcCtD
Asenapine—HRH2—digestive system—esophageal cancer	0.00479	0.0215	CbGeAlD
Asenapine—HTR7—neck—esophageal cancer	0.00471	0.0212	CbGeAlD
Asenapine—Hypertriglyceridaemia—Capecitabine—esophageal cancer	0.00423	0.0181	CcSEcCtD
Asenapine—HRH2—lung—esophageal cancer	0.004	0.018	CbGeAlD
Asenapine—Liver injury—Cisplatin—esophageal cancer	0.00391	0.0167	CcSEcCtD
Asenapine—ADRB1—bronchus—esophageal cancer	0.00385	0.0173	CbGeAlD
Asenapine—Blood triglycerides increased—Capecitabine—esophageal cancer	0.0037	0.0158	CcSEcCtD
Asenapine—HTR2B—smooth muscle tissue—esophageal cancer	0.0036	0.0162	CbGeAlD
Asenapine—Dysarthria—Cisplatin—esophageal cancer	0.00348	0.0149	CcSEcCtD
Asenapine—Ulcer—Cisplatin—esophageal cancer	0.00348	0.0149	CcSEcCtD
Asenapine—Blister—Capecitabine—esophageal cancer	0.00337	0.0144	CcSEcCtD
Asenapine—HTR7—epithelium—esophageal cancer	0.0032	0.0144	CbGeAlD
Asenapine—Wheezing—Cisplatin—esophageal cancer	0.0032	0.0137	CcSEcCtD
Asenapine—Skin exfoliation—Cisplatin—esophageal cancer	0.00314	0.0134	CcSEcCtD
Asenapine—ADRA1A—epithelium—esophageal cancer	0.00309	0.0139	CbGeAlD
Asenapine—HTR7—smooth muscle tissue—esophageal cancer	0.00309	0.0139	CbGeAlD
Asenapine—HTR2A—neck—esophageal cancer	0.00294	0.0132	CbGeAlD
Asenapine—ADRA2C—bronchus—esophageal cancer	0.0029	0.013	CbGeAlD
Asenapine—SLC6A4—digestive system—esophageal cancer	0.00287	0.0129	CbGeAlD
Asenapine—HTR2B—digestive system—esophageal cancer	0.00285	0.0128	CbGeAlD
Asenapine—HTR7—trachea—esophageal cancer	0.00283	0.0127	CbGeAlD
Asenapine—HRH2—lymph node—esophageal cancer	0.00274	0.0123	CbGeAlD
Asenapine—ADRA2C—trachea—esophageal cancer	0.0026	0.0117	CbGeAlD
Asenapine—Dysarthria—Capecitabine—esophageal cancer	0.00257	0.011	CcSEcCtD
Asenapine—Ulcer—Capecitabine—esophageal cancer	0.00257	0.011	CcSEcCtD
Asenapine—Inflammation—Capecitabine—esophageal cancer	0.0025	0.0107	CcSEcCtD
Asenapine—ADRB1—lung—esophageal cancer	0.00248	0.0112	CbGeAlD
Asenapine—Anaphylactoid reaction—Cisplatin—esophageal cancer	0.00247	0.0106	CcSEcCtD
Asenapine—HTR7—digestive system—esophageal cancer	0.00244	0.011	CbGeAlD
Asenapine—Pulmonary embolism—Capecitabine—esophageal cancer	0.00243	0.0104	CcSEcCtD
Asenapine—Hyponatraemia—Cisplatin—esophageal cancer	0.0024	0.0103	CcSEcCtD
Asenapine—SLC6A4—lung—esophageal cancer	0.0024	0.0108	CbGeAlD
Asenapine—HRH1—epithelium—esophageal cancer	0.00239	0.0107	CbGeAlD
Asenapine—HTR2B—lung—esophageal cancer	0.00238	0.0107	CbGeAlD
Asenapine—Skin exfoliation—Capecitabine—esophageal cancer	0.00232	0.00991	CcSEcCtD
Asenapine—ADRA2A—bronchus—esophageal cancer	0.00231	0.0104	CbGeAlD
Asenapine—HRH1—smooth muscle tissue—esophageal cancer	0.0023	0.0104	CbGeAlD
Asenapine—Irritability—Cisplatin—esophageal cancer	0.00228	0.00976	CcSEcCtD
Asenapine—Mouth ulceration—Capecitabine—esophageal cancer	0.00219	0.00938	CcSEcCtD
Asenapine—Orthostatic hypotension—Cisplatin—esophageal cancer	0.00218	0.00934	CcSEcCtD
Asenapine—Breast disorder—Cisplatin—esophageal cancer	0.00216	0.00924	CcSEcCtD
Asenapine—HRH1—trachea—esophageal cancer	0.00211	0.0095	CbGeAlD
Asenapine—ADRA2A—trachea—esophageal cancer	0.00208	0.00934	CbGeAlD
Asenapine—HTR7—lung—esophageal cancer	0.00203	0.00915	CbGeAlD
Asenapine—Diabetes mellitus—Capecitabine—esophageal cancer	0.00203	0.00866	CcSEcCtD
Asenapine—Swelling—Capecitabine—esophageal cancer	0.002	0.00854	CcSEcCtD
Asenapine—HTR2A—epithelium—esophageal cancer	0.002	0.00898	CbGeAlD
Asenapine—Abdominal discomfort—Cisplatin—esophageal cancer	0.00198	0.00847	CcSEcCtD
Asenapine—CYP1A2—digestive system—esophageal cancer	0.00194	0.00873	CbGeAlD
Asenapine—HTR2A—smooth muscle tissue—esophageal cancer	0.00192	0.00865	CbGeAlD
Asenapine—DRD2—lung—esophageal cancer	0.00192	0.00865	CbGeAlD
Asenapine—Dysarthria—Methotrexate—esophageal cancer	0.00191	0.00817	CcSEcCtD
Asenapine—Ulcer—Methotrexate—esophageal cancer	0.00191	0.00817	CcSEcCtD
Asenapine—Increased appetite—Capecitabine—esophageal cancer	0.00188	0.00802	CcSEcCtD
Asenapine—ADRA2C—lung—esophageal cancer	0.00187	0.00841	CbGeAlD
Asenapine—Inflammation—Methotrexate—esophageal cancer	0.00186	0.00797	CcSEcCtD
Asenapine—Dermatitis bullous—Capecitabine—esophageal cancer	0.00184	0.00788	CcSEcCtD
Asenapine—HRH1—digestive system—esophageal cancer	0.00182	0.00818	CbGeAlD
Asenapine—Pulmonary embolism—Methotrexate—esophageal cancer	0.00181	0.00773	CcSEcCtD
Asenapine—Stomatitis—Cisplatin—esophageal cancer	0.0018	0.00768	CcSEcCtD
Asenapine—Hyponatraemia—Capecitabine—esophageal cancer	0.00177	0.00756	CcSEcCtD
Asenapine—HTR2A—trachea—esophageal cancer	0.00177	0.00794	CbGeAlD
Asenapine—Osteoarthritis—Capecitabine—esophageal cancer	0.00176	0.00753	CcSEcCtD
Asenapine—Pain in extremity—Capecitabine—esophageal cancer	0.00176	0.00753	CcSEcCtD
Asenapine—Hepatobiliary disease—Cisplatin—esophageal cancer	0.00174	0.00745	CcSEcCtD
Asenapine—Skin exfoliation—Methotrexate—esophageal cancer	0.00173	0.00738	CcSEcCtD
Asenapine—Irritability—Capecitabine—esophageal cancer	0.00168	0.00719	CcSEcCtD
Asenapine—Mouth ulceration—Methotrexate—esophageal cancer	0.00163	0.00699	CcSEcCtD
Asenapine—HTR2B—lymph node—esophageal cancer	0.00163	0.00731	CbGeAlD
Asenapine—Connective tissue disorder—Cisplatin—esophageal cancer	0.00163	0.00695	CcSEcCtD
Asenapine—CYP1A2—lung—esophageal cancer	0.00162	0.00729	CbGeAlD
Asenapine—Gynaecomastia—Methotrexate—esophageal cancer	0.00162	0.00691	CcSEcCtD
Asenapine—Orthostatic hypotension—Capecitabine—esophageal cancer	0.00161	0.00688	CcSEcCtD
Asenapine—Breast disorder—Capecitabine—esophageal cancer	0.00159	0.00681	CcSEcCtD
Asenapine—Alanine aminotransferase increased—Capecitabine—esophageal cancer	0.00155	0.00665	CcSEcCtD
Asenapine—Eye disorder—Cisplatin—esophageal cancer	0.00155	0.00661	CcSEcCtD
Asenapine—Cardiac disorder—Cisplatin—esophageal cancer	0.00153	0.00656	CcSEcCtD
Asenapine—Dysphagia—Capecitabine—esophageal cancer	0.00152	0.00651	CcSEcCtD
Asenapine—HTR2A—digestive system—esophageal cancer	0.00152	0.00683	CbGeAlD
Asenapine—HRH1—lung—esophageal cancer	0.00152	0.00683	CbGeAlD
Asenapine—Diabetes mellitus—Methotrexate—esophageal cancer	0.00151	0.00645	CcSEcCtD
Asenapine—Immune system disorder—Cisplatin—esophageal cancer	0.00149	0.00639	CcSEcCtD
Asenapine—ADRA2A—lung—esophageal cancer	0.00149	0.00671	CbGeAlD
Asenapine—Mediastinal disorder—Cisplatin—esophageal cancer	0.00149	0.00637	CcSEcCtD
Asenapine—Abdominal discomfort—Capecitabine—esophageal cancer	0.00146	0.00624	CcSEcCtD
Asenapine—Malnutrition—Cisplatin—esophageal cancer	0.00144	0.00616	CcSEcCtD
Asenapine—Neutropenia—Capecitabine—esophageal cancer	0.00142	0.00609	CcSEcCtD
Asenapine—CYP3A4—digestive system—esophageal cancer	0.00141	0.00632	CbGeAlD
Asenapine—Weight increased—Capecitabine—esophageal cancer	0.00139	0.00593	CcSEcCtD
Asenapine—CYP2D6—digestive system—esophageal cancer	0.00138	0.00622	CbGeAlD
Asenapine—Muscle spasms—Cisplatin—esophageal cancer	0.00138	0.00592	CcSEcCtD
Asenapine—Hyperglycaemia—Capecitabine—esophageal cancer	0.00137	0.00587	CcSEcCtD
Asenapine—Anaphylactoid reaction—Methotrexate—esophageal cancer	0.00136	0.0058	CcSEcCtD
Asenapine—Depression—Capecitabine—esophageal cancer	0.00135	0.00579	CcSEcCtD
Asenapine—Tremor—Cisplatin—esophageal cancer	0.00135	0.00577	CcSEcCtD
Asenapine—Anaemia—Cisplatin—esophageal cancer	0.00133	0.00569	CcSEcCtD
Asenapine—Stomatitis—Capecitabine—esophageal cancer	0.00132	0.00566	CcSEcCtD
Asenapine—Osteoarthritis—Methotrexate—esophageal cancer	0.00131	0.00561	CcSEcCtD
Asenapine—Malaise—Cisplatin—esophageal cancer	0.0013	0.00555	CcSEcCtD
Asenapine—Leukopenia—Cisplatin—esophageal cancer	0.00129	0.00551	CcSEcCtD
Asenapine—Hepatobiliary disease—Capecitabine—esophageal cancer	0.00128	0.00549	CcSEcCtD
Asenapine—ADRA2C—lymph node—esophageal cancer	0.00128	0.00575	CbGeAlD
Asenapine—HTR2A—lung—esophageal cancer	0.00127	0.0057	CbGeAlD
Asenapine—Agranulocytosis—Capecitabine—esophageal cancer	0.00127	0.00542	CcSEcCtD
Asenapine—Irritability—Methotrexate—esophageal cancer	0.00125	0.00535	CcSEcCtD
Asenapine—Convulsion—Cisplatin—esophageal cancer	0.00125	0.00533	CcSEcCtD
Asenapine—Anxiety—Cisplatin—esophageal cancer	0.00122	0.00522	CcSEcCtD
Asenapine—Oedema peripheral—Capecitabine—esophageal cancer	0.0012	0.00513	CcSEcCtD
Asenapine—Connective tissue disorder—Capecitabine—esophageal cancer	0.0012	0.00512	CcSEcCtD
Asenapine—Breast disorder—Methotrexate—esophageal cancer	0.00119	0.00507	CcSEcCtD
Asenapine—Anaphylactic shock—Cisplatin—esophageal cancer	0.00117	0.00502	CcSEcCtD
Asenapine—Nervous system disorder—Cisplatin—esophageal cancer	0.00115	0.00493	CcSEcCtD
Asenapine—Thrombocytopenia—Cisplatin—esophageal cancer	0.00115	0.00492	CcSEcCtD
Asenapine—Tachycardia—Cisplatin—esophageal cancer	0.00115	0.0049	CcSEcCtD
Asenapine—Eye disorder—Capecitabine—esophageal cancer	0.00114	0.00487	CcSEcCtD
Asenapine—Cardiac disorder—Capecitabine—esophageal cancer	0.00113	0.00484	CcSEcCtD
Asenapine—Angiopathy—Capecitabine—esophageal cancer	0.00111	0.00473	CcSEcCtD
Asenapine—Immune system disorder—Capecitabine—esophageal cancer	0.0011	0.00471	CcSEcCtD
Asenapine—Mediastinal disorder—Capecitabine—esophageal cancer	0.0011	0.0047	CcSEcCtD
Asenapine—Hypotension—Cisplatin—esophageal cancer	0.0011	0.00469	CcSEcCtD
Asenapine—Abdominal discomfort—Methotrexate—esophageal cancer	0.00109	0.00465	CcSEcCtD
Asenapine—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.00107	0.00458	CcSEcCtD
Asenapine—Mental disorder—Capecitabine—esophageal cancer	0.00107	0.00457	CcSEcCtD
Asenapine—Malnutrition—Capecitabine—esophageal cancer	0.00106	0.00454	CcSEcCtD
Asenapine—Neutropenia—Methotrexate—esophageal cancer	0.00106	0.00453	CcSEcCtD
Asenapine—Dyspnoea—Cisplatin—esophageal cancer	0.00105	0.00448	CcSEcCtD
Asenapine—Dysgeusia—Capecitabine—esophageal cancer	0.00104	0.00444	CcSEcCtD
Asenapine—HRH1—lymph node—esophageal cancer	0.00104	0.00467	CbGeAlD
Asenapine—ADRA2A—lymph node—esophageal cancer	0.00102	0.00459	CbGeAlD
Asenapine—Muscle spasms—Capecitabine—esophageal cancer	0.00102	0.00436	CcSEcCtD
Asenapine—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.00101	0.00434	CcSEcCtD
Asenapine—Depression—Methotrexate—esophageal cancer	0.00101	0.00431	CcSEcCtD
Asenapine—Tremor—Capecitabine—esophageal cancer	0.000994	0.00425	CcSEcCtD
Asenapine—Stomatitis—Methotrexate—esophageal cancer	0.000985	0.00421	CcSEcCtD
Asenapine—Anaemia—Capecitabine—esophageal cancer	0.000981	0.00419	CcSEcCtD
Asenapine—Malaise—Capecitabine—esophageal cancer	0.000957	0.00409	CcSEcCtD
Asenapine—Hepatobiliary disease—Methotrexate—esophageal cancer	0.000956	0.00409	CcSEcCtD
Asenapine—Syncope—Capecitabine—esophageal cancer	0.000952	0.00407	CcSEcCtD
Asenapine—Leukopenia—Capecitabine—esophageal cancer	0.00095	0.00406	CcSEcCtD
Asenapine—Agranulocytosis—Methotrexate—esophageal cancer	0.000943	0.00403	CcSEcCtD
Asenapine—Loss of consciousness—Capecitabine—esophageal cancer	0.000933	0.00399	CcSEcCtD
Asenapine—Hypertension—Capecitabine—esophageal cancer	0.000916	0.00392	CcSEcCtD
Asenapine—Arthralgia—Capecitabine—esophageal cancer	0.000903	0.00386	CcSEcCtD
Asenapine—Anxiety—Capecitabine—esophageal cancer	0.0009	0.00385	CcSEcCtD
Asenapine—Dry mouth—Capecitabine—esophageal cancer	0.000884	0.00378	CcSEcCtD
Asenapine—Hypersensitivity—Cisplatin—esophageal cancer	0.000866	0.0037	CcSEcCtD
Asenapine—Shock—Capecitabine—esophageal cancer	0.000852	0.00364	CcSEcCtD
Asenapine—Nervous system disorder—Capecitabine—esophageal cancer	0.000849	0.00363	CcSEcCtD
Asenapine—Eye disorder—Methotrexate—esophageal cancer	0.000848	0.00363	CcSEcCtD
Asenapine—Thrombocytopenia—Capecitabine—esophageal cancer	0.000848	0.00363	CcSEcCtD
Asenapine—Tachycardia—Capecitabine—esophageal cancer	0.000845	0.00361	CcSEcCtD
Asenapine—Asthenia—Cisplatin—esophageal cancer	0.000843	0.0036	CcSEcCtD
Asenapine—Cardiac disorder—Methotrexate—esophageal cancer	0.000842	0.0036	CcSEcCtD
Asenapine—Angiopathy—Methotrexate—esophageal cancer	0.000823	0.00352	CcSEcCtD
Asenapine—Immune system disorder—Methotrexate—esophageal cancer	0.00082	0.0035	CcSEcCtD
Asenapine—Mediastinal disorder—Methotrexate—esophageal cancer	0.000818	0.0035	CcSEcCtD
Asenapine—Hypotension—Capecitabine—esophageal cancer	0.000809	0.00346	CcSEcCtD
Asenapine—Mental disorder—Methotrexate—esophageal cancer	0.000795	0.0034	CcSEcCtD
Asenapine—Malnutrition—Methotrexate—esophageal cancer	0.00079	0.00338	CcSEcCtD
Asenapine—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000789	0.00337	CcSEcCtD
Asenapine—Insomnia—Capecitabine—esophageal cancer	0.000783	0.00335	CcSEcCtD
Asenapine—Dysgeusia—Methotrexate—esophageal cancer	0.000774	0.00331	CcSEcCtD
Asenapine—Dyspnoea—Capecitabine—esophageal cancer	0.000772	0.0033	CcSEcCtD
Asenapine—Dyspepsia—Capecitabine—esophageal cancer	0.000762	0.00326	CcSEcCtD
Asenapine—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000748	0.0032	CcSEcCtD
Asenapine—Vomiting—Cisplatin—esophageal cancer	0.000747	0.00319	CcSEcCtD
Asenapine—Fatigue—Capecitabine—esophageal cancer	0.000747	0.00319	CcSEcCtD
Asenapine—Rash—Cisplatin—esophageal cancer	0.000741	0.00317	CcSEcCtD
Asenapine—Constipation—Capecitabine—esophageal cancer	0.000741	0.00317	CcSEcCtD
Asenapine—Dermatitis—Cisplatin—esophageal cancer	0.00074	0.00316	CcSEcCtD
Asenapine—Anaemia—Methotrexate—esophageal cancer	0.00073	0.00312	CcSEcCtD
Asenapine—Malaise—Methotrexate—esophageal cancer	0.000712	0.00305	CcSEcCtD
Asenapine—Leukopenia—Methotrexate—esophageal cancer	0.000707	0.00302	CcSEcCtD
Asenapine—Nausea—Cisplatin—esophageal cancer	0.000698	0.00298	CcSEcCtD
Asenapine—Convulsion—Methotrexate—esophageal cancer	0.000684	0.00293	CcSEcCtD
Asenapine—Arthralgia—Methotrexate—esophageal cancer	0.000673	0.00288	CcSEcCtD
Asenapine—Anaphylactic shock—Methotrexate—esophageal cancer	0.000645	0.00276	CcSEcCtD
Asenapine—Hypersensitivity—Capecitabine—esophageal cancer	0.000638	0.00273	CcSEcCtD
Asenapine—Nervous system disorder—Methotrexate—esophageal cancer	0.000632	0.0027	CcSEcCtD
Asenapine—Thrombocytopenia—Methotrexate—esophageal cancer	0.000631	0.0027	CcSEcCtD
Asenapine—Asthenia—Capecitabine—esophageal cancer	0.000621	0.00266	CcSEcCtD
Asenapine—Hypotension—Methotrexate—esophageal cancer	0.000602	0.00258	CcSEcCtD
Asenapine—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000587	0.00251	CcSEcCtD
Asenapine—Insomnia—Methotrexate—esophageal cancer	0.000583	0.00249	CcSEcCtD
Asenapine—Dyspnoea—Methotrexate—esophageal cancer	0.000575	0.00246	CcSEcCtD
Asenapine—Somnolence—Methotrexate—esophageal cancer	0.000573	0.00245	CcSEcCtD
Asenapine—Dizziness—Capecitabine—esophageal cancer	0.000573	0.00245	CcSEcCtD
Asenapine—Dyspepsia—Methotrexate—esophageal cancer	0.000567	0.00243	CcSEcCtD
Asenapine—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000557	0.00238	CcSEcCtD
Asenapine—Fatigue—Methotrexate—esophageal cancer	0.000556	0.00238	CcSEcCtD
Asenapine—Vomiting—Capecitabine—esophageal cancer	0.000551	0.00235	CcSEcCtD
Asenapine—Rash—Capecitabine—esophageal cancer	0.000546	0.00233	CcSEcCtD
Asenapine—Dermatitis—Capecitabine—esophageal cancer	0.000546	0.00233	CcSEcCtD
Asenapine—Headache—Capecitabine—esophageal cancer	0.000543	0.00232	CcSEcCtD
Asenapine—Nausea—Capecitabine—esophageal cancer	0.000514	0.0022	CcSEcCtD
Asenapine—Hypersensitivity—Methotrexate—esophageal cancer	0.000475	0.00203	CcSEcCtD
Asenapine—Asthenia—Methotrexate—esophageal cancer	0.000463	0.00198	CcSEcCtD
Asenapine—Dizziness—Methotrexate—esophageal cancer	0.000426	0.00182	CcSEcCtD
Asenapine—Vomiting—Methotrexate—esophageal cancer	0.00041	0.00175	CcSEcCtD
Asenapine—Rash—Methotrexate—esophageal cancer	0.000406	0.00174	CcSEcCtD
Asenapine—Dermatitis—Methotrexate—esophageal cancer	0.000406	0.00174	CcSEcCtD
Asenapine—Headache—Methotrexate—esophageal cancer	0.000404	0.00173	CcSEcCtD
Asenapine—Nausea—Methotrexate—esophageal cancer	0.000383	0.00164	CcSEcCtD
Asenapine—HTR7—Signaling Pathways—CCND1—esophageal cancer	2.5e-05	4.6e-05	CbGpPWpGaD
Asenapine—HTR1E—Signaling Pathways—PIK3CA—esophageal cancer	2.49e-05	4.59e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—CREBBP—esophageal cancer	2.49e-05	4.58e-05	CbGpPWpGaD
Asenapine—HTR1D—Signaling Pathways—CCND1—esophageal cancer	2.48e-05	4.57e-05	CbGpPWpGaD
Asenapine—DRD1—Signaling by GPCR—PIK3CA—esophageal cancer	2.48e-05	4.57e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—KDR—esophageal cancer	2.48e-05	4.56e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling by GPCR—EGFR—esophageal cancer	2.46e-05	4.52e-05	CbGpPWpGaD
Asenapine—ADRB1—GPCR downstream signaling—PIK3CA—esophageal cancer	2.46e-05	4.52e-05	CbGpPWpGaD
Asenapine—DRD3—Signaling by GPCR—PIK3CA—esophageal cancer	2.45e-05	4.51e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling by GPCR—EGFR—esophageal cancer	2.45e-05	4.5e-05	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—ERBB2—esophageal cancer	2.44e-05	4.48e-05	CbGpPWpGaD
Asenapine—ADRA2B—GPCR downstream signaling—PIK3CA—esophageal cancer	2.44e-05	4.48e-05	CbGpPWpGaD
Asenapine—HTR1B—Signaling Pathways—CCND1—esophageal cancer	2.43e-05	4.47e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—NOTCH1—esophageal cancer	2.42e-05	4.46e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—CREBBP—esophageal cancer	2.42e-05	4.45e-05	CbGpPWpGaD
Asenapine—HTR6—Signaling Pathways—CDKN1A—esophageal cancer	2.42e-05	4.45e-05	CbGpPWpGaD
Asenapine—HTR7—Signaling Pathways—CDKN1A—esophageal cancer	2.42e-05	4.45e-05	CbGpPWpGaD
Asenapine—HTR1E—Signaling Pathways—TP53—esophageal cancer	2.41e-05	4.44e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—HIF1A—esophageal cancer	2.41e-05	4.43e-05	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—ERBB2—esophageal cancer	2.41e-05	4.42e-05	CbGpPWpGaD
Asenapine—ADRB2—GPCR downstream signaling—PIK3CA—esophageal cancer	2.4e-05	4.42e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—ALDH2—esophageal cancer	2.4e-05	4.42e-05	CbGpPWpGaD
Asenapine—HTR1D—Signaling Pathways—CDKN1A—esophageal cancer	2.4e-05	4.42e-05	CbGpPWpGaD
Asenapine—DRD4—Signaling Pathways—CCND1—esophageal cancer	2.39e-05	4.4e-05	CbGpPWpGaD
Asenapine—CYP2D6—Metabolism—HMOX1—esophageal cancer	2.39e-05	4.4e-05	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	2.39e-05	4.39e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—NOTCH1—esophageal cancer	2.38e-05	4.39e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling by GPCR—EGFR—esophageal cancer	2.38e-05	4.38e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—NOTCH1—esophageal cancer	2.38e-05	4.38e-05	CbGpPWpGaD
Asenapine—ADRA2C—Metabolism—PTGS2—esophageal cancer	2.37e-05	4.36e-05	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—CYP1B1—esophageal cancer	2.36e-05	4.34e-05	CbGpPWpGaD
Asenapine—ADRA2A—Metabolism—CREBBP—esophageal cancer	2.35e-05	4.33e-05	CbGpPWpGaD
Asenapine—HTR1B—Signaling Pathways—CDKN1A—esophageal cancer	2.35e-05	4.33e-05	CbGpPWpGaD
Asenapine—HTR1A—GPCR downstream signaling—PIK3CA—esophageal cancer	2.35e-05	4.32e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—NOS3—esophageal cancer	2.34e-05	4.31e-05	CbGpPWpGaD
Asenapine—HTR2C—GPCR downstream signaling—PIK3CA—esophageal cancer	2.34e-05	4.3e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—NOTCH1—esophageal cancer	2.34e-05	4.3e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—NOS3—esophageal cancer	2.32e-05	4.27e-05	CbGpPWpGaD
Asenapine—DRD4—Signaling Pathways—CDKN1A—esophageal cancer	2.31e-05	4.26e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—KDR—esophageal cancer	2.3e-05	4.24e-05	CbGpPWpGaD
Asenapine—HTR6—Signaling Pathways—EP300—esophageal cancer	2.3e-05	4.24e-05	CbGpPWpGaD
Asenapine—HTR7—Signaling Pathways—EP300—esophageal cancer	2.3e-05	4.23e-05	CbGpPWpGaD
Asenapine—CYP2D6—Metabolism—ABCB1—esophageal cancer	2.29e-05	4.22e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—NOS3—esophageal cancer	2.29e-05	4.22e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—GSTT1—esophageal cancer	2.29e-05	4.2e-05	CbGpPWpGaD
Asenapine—HTR1D—Signaling Pathways—EP300—esophageal cancer	2.29e-05	4.2e-05	CbGpPWpGaD
Asenapine—HTR2B—Signaling Pathways—CCND1—esophageal cancer	2.28e-05	4.2e-05	CbGpPWpGaD
Asenapine—ADRA2C—GPCR downstream signaling—PIK3CA—esophageal cancer	2.27e-05	4.18e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—CYP2A6—esophageal cancer	2.26e-05	4.16e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—NOS3—esophageal cancer	2.24e-05	4.12e-05	CbGpPWpGaD
Asenapine—HTR1B—Signaling Pathways—EP300—esophageal cancer	2.24e-05	4.12e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling by GPCR—PIK3CA—esophageal cancer	2.23e-05	4.1e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—NOS3—esophageal cancer	2.23e-05	4.1e-05	CbGpPWpGaD
Asenapine—HRH2—Signaling Pathways—PIK3CA—esophageal cancer	2.22e-05	4.09e-05	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—CYP19A1—esophageal cancer	2.22e-05	4.08e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling by GPCR—PIK3CA—esophageal cancer	2.21e-05	4.07e-05	CbGpPWpGaD
Asenapine—HTR2B—Signaling Pathways—CDKN1A—esophageal cancer	2.21e-05	4.06e-05	CbGpPWpGaD
Asenapine—DRD4—Signaling Pathways—EP300—esophageal cancer	2.2e-05	4.05e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—CREBBP—esophageal cancer	2.2e-05	4.04e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—ERBB2—esophageal cancer	2.19e-05	4.03e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling by GPCR—PIK3CA—esophageal cancer	2.18e-05	4.02e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—ERBB2—esophageal cancer	2.17e-05	3.99e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—NOTCH1—esophageal cancer	2.17e-05	3.99e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—NOS3—esophageal cancer	2.17e-05	3.99e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—CREBBP—esophageal cancer	2.16e-05	3.98e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling by GPCR—EGFR—esophageal cancer	2.16e-05	3.97e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—CREBBP—esophageal cancer	2.16e-05	3.97e-05	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—CCND1—esophageal cancer	2.15e-05	3.96e-05	CbGpPWpGaD
Asenapine—HRH2—Signaling Pathways—TP53—esophageal cancer	2.15e-05	3.95e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—ERBB2—esophageal cancer	2.14e-05	3.94e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—PTGS1—esophageal cancer	2.14e-05	3.94e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—ENO1—esophageal cancer	2.14e-05	3.94e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling by GPCR—PIK3CA—esophageal cancer	2.13e-05	3.93e-05	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—CCND1—esophageal cancer	2.12e-05	3.91e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling by GPCR—EGFR—esophageal cancer	2.12e-05	3.91e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling by GPCR—PIK3CA—esophageal cancer	2.12e-05	3.91e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling by GPCR—EGFR—esophageal cancer	2.12e-05	3.9e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—CREBBP—esophageal cancer	2.12e-05	3.89e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—PSME2—esophageal cancer	2.11e-05	3.88e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—PSME1—esophageal cancer	2.11e-05	3.88e-05	CbGpPWpGaD
Asenapine—ADRA2A—Metabolism—NOS3—esophageal cancer	2.11e-05	3.87e-05	CbGpPWpGaD
Asenapine—HTR2B—Signaling Pathways—EP300—esophageal cancer	2.1e-05	3.87e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—ERBB2—esophageal cancer	2.1e-05	3.86e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—ERBB2—esophageal cancer	2.09e-05	3.84e-05	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—CDKN1A—esophageal cancer	2.08e-05	3.83e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling by GPCR—EGFR—esophageal cancer	2.08e-05	3.83e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling by GPCR—PIK3CA—esophageal cancer	2.07e-05	3.8e-05	CbGpPWpGaD
Asenapine—DRD2—GPCR downstream signaling—PIK3CA—esophageal cancer	2.06e-05	3.8e-05	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—CDKN1A—esophageal cancer	2.06e-05	3.78e-05	CbGpPWpGaD
Asenapine—HTR2A—GPCR downstream signaling—PIK3CA—esophageal cancer	2.03e-05	3.74e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—ERBB2—esophageal cancer	2.03e-05	3.73e-05	CbGpPWpGaD
Asenapine—HRH1—GPCR downstream signaling—PIK3CA—esophageal cancer	2.03e-05	3.73e-05	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—HMOX1—esophageal cancer	2.02e-05	3.72e-05	CbGpPWpGaD
Asenapine—HTR6—Signaling Pathways—MYC—esophageal cancer	2.01e-05	3.69e-05	CbGpPWpGaD
Asenapine—HTR7—Signaling Pathways—MYC—esophageal cancer	2e-05	3.69e-05	CbGpPWpGaD
Asenapine—HTR1D—Signaling Pathways—MYC—esophageal cancer	1.99e-05	3.66e-05	CbGpPWpGaD
Asenapine—ADRA1A—GPCR downstream signaling—PIK3CA—esophageal cancer	1.99e-05	3.66e-05	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.99e-05	3.65e-05	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—EP300—esophageal cancer	1.98e-05	3.65e-05	CbGpPWpGaD
Asenapine—ADRA2C—Metabolism—EP300—esophageal cancer	1.97e-05	3.63e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—NOS3—esophageal cancer	1.97e-05	3.62e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—CREBBP—esophageal cancer	1.97e-05	3.62e-05	CbGpPWpGaD
Asenapine—HTR6—Signaling Pathways—EGFR—esophageal cancer	1.96e-05	3.61e-05	CbGpPWpGaD
Asenapine—HTR7—Signaling Pathways—EGFR—esophageal cancer	1.96e-05	3.61e-05	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—EP300—esophageal cancer	1.96e-05	3.6e-05	CbGpPWpGaD
Asenapine—HTR1B—Signaling Pathways—MYC—esophageal cancer	1.95e-05	3.59e-05	CbGpPWpGaD
Asenapine—HTR1D—Signaling Pathways—EGFR—esophageal cancer	1.95e-05	3.58e-05	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—ABCB1—esophageal cancer	1.94e-05	3.57e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—CCND1—esophageal cancer	1.94e-05	3.56e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—NOS3—esophageal cancer	1.94e-05	3.56e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling by GPCR—EGFR—esophageal cancer	1.93e-05	3.56e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—NOS3—esophageal cancer	1.93e-05	3.55e-05	CbGpPWpGaD
Asenapine—ADRA2A—Metabolism—PTGS2—esophageal cancer	1.93e-05	3.54e-05	CbGpPWpGaD
Asenapine—DRD4—Signaling Pathways—MYC—esophageal cancer	1.92e-05	3.53e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—CCND1—esophageal cancer	1.92e-05	3.53e-05	CbGpPWpGaD
Asenapine—HTR1B—Signaling Pathways—EGFR—esophageal cancer	1.91e-05	3.51e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—NOS3—esophageal cancer	1.9e-05	3.49e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—CCND1—esophageal cancer	1.89e-05	3.48e-05	CbGpPWpGaD
Asenapine—DRD4—Signaling Pathways—EGFR—esophageal cancer	1.88e-05	3.45e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling by GPCR—PIK3CA—esophageal cancer	1.87e-05	3.45e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—CDKN1A—esophageal cancer	1.87e-05	3.45e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—CDKN1A—esophageal cancer	1.86e-05	3.41e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—CCND1—esophageal cancer	1.85e-05	3.41e-05	CbGpPWpGaD
Asenapine—ADRA2A—GPCR downstream signaling—PIK3CA—esophageal cancer	1.85e-05	3.4e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling by GPCR—PIK3CA—esophageal cancer	1.84e-05	3.39e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—CCND1—esophageal cancer	1.84e-05	3.39e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—ERBB2—esophageal cancer	1.84e-05	3.39e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling by GPCR—PIK3CA—esophageal cancer	1.84e-05	3.38e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—CDKN1A—esophageal cancer	1.83e-05	3.37e-05	CbGpPWpGaD
Asenapine—HTR2B—Signaling Pathways—MYC—esophageal cancer	1.83e-05	3.37e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—CYP1B1—esophageal cancer	1.82e-05	3.35e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—ERBB2—esophageal cancer	1.81e-05	3.33e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—ERBB2—esophageal cancer	1.81e-05	3.32e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling by GPCR—PIK3CA—esophageal cancer	1.81e-05	3.32e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—CCND1—esophageal cancer	1.79e-05	3.3e-05	CbGpPWpGaD
Asenapine—HTR2B—Signaling Pathways—EGFR—esophageal cancer	1.79e-05	3.3e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—CDKN1A—esophageal cancer	1.79e-05	3.3e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—CDKN1A—esophageal cancer	1.78e-05	3.28e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—EP300—esophageal cancer	1.78e-05	3.28e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—ERBB2—esophageal cancer	1.77e-05	3.26e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—EP300—esophageal cancer	1.77e-05	3.25e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—NOS3—esophageal cancer	1.76e-05	3.24e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—EP300—esophageal cancer	1.74e-05	3.21e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—CDKN1A—esophageal cancer	1.73e-05	3.19e-05	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—MYC—esophageal cancer	1.73e-05	3.18e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—CYP19A1—esophageal cancer	1.71e-05	3.15e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—EP300—esophageal cancer	1.7e-05	3.14e-05	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—MYC—esophageal cancer	1.7e-05	3.14e-05	CbGpPWpGaD
Asenapine—HTR6—Signaling Pathways—PIK3CA—esophageal cancer	1.7e-05	3.13e-05	CbGpPWpGaD
Asenapine—HTR7—Signaling Pathways—PIK3CA—esophageal cancer	1.7e-05	3.13e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—EP300—esophageal cancer	1.7e-05	3.12e-05	CbGpPWpGaD
Asenapine—HTR1D—Signaling Pathways—PIK3CA—esophageal cancer	1.69e-05	3.11e-05	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—EGFR—esophageal cancer	1.69e-05	3.11e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling by GPCR—PIK3CA—esophageal cancer	1.68e-05	3.09e-05	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—EGFR—esophageal cancer	1.67e-05	3.07e-05	CbGpPWpGaD
Asenapine—HTR1B—Signaling Pathways—PIK3CA—esophageal cancer	1.66e-05	3.04e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—EP300—esophageal cancer	1.65e-05	3.03e-05	CbGpPWpGaD
Asenapine—HTR6—Signaling Pathways—TP53—esophageal cancer	1.65e-05	3.03e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—ERBB2—esophageal cancer	1.65e-05	3.03e-05	CbGpPWpGaD
Asenapine—HTR7—Signaling Pathways—TP53—esophageal cancer	1.65e-05	3.03e-05	CbGpPWpGaD
Asenapine—HTR1D—Signaling Pathways—TP53—esophageal cancer	1.64e-05	3.01e-05	CbGpPWpGaD
Asenapine—DRD4—Signaling Pathways—PIK3CA—esophageal cancer	1.63e-05	3e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—CCND1—esophageal cancer	1.63e-05	2.99e-05	CbGpPWpGaD
Asenapine—ADRA2A—Metabolism—EP300—esophageal cancer	1.6e-05	2.95e-05	CbGpPWpGaD
Asenapine—HTR1B—Signaling Pathways—TP53—esophageal cancer	1.6e-05	2.95e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—CCND1—esophageal cancer	1.6e-05	2.94e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—CCND1—esophageal cancer	1.6e-05	2.94e-05	CbGpPWpGaD
Asenapine—DRD4—Signaling Pathways—TP53—esophageal cancer	1.58e-05	2.9e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—CDKN1A—esophageal cancer	1.57e-05	2.89e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—CCND1—esophageal cancer	1.57e-05	2.88e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—HMOX1—esophageal cancer	1.56e-05	2.87e-05	CbGpPWpGaD
Asenapine—HTR2B—Signaling Pathways—PIK3CA—esophageal cancer	1.55e-05	2.86e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—MYC—esophageal cancer	1.55e-05	2.86e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—CDKN1A—esophageal cancer	1.55e-05	2.85e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—CDKN1A—esophageal cancer	1.54e-05	2.84e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—MYC—esophageal cancer	1.54e-05	2.83e-05	CbGpPWpGaD
Asenapine—CYP2D6—Metabolism—CREBBP—esophageal cancer	1.53e-05	2.82e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—MYC—esophageal cancer	1.52e-05	2.79e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—EGFR—esophageal cancer	1.52e-05	2.79e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—CDKN1A—esophageal cancer	1.52e-05	2.79e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—EGFR—esophageal cancer	1.51e-05	2.77e-05	CbGpPWpGaD
Asenapine—HTR2B—Signaling Pathways—TP53—esophageal cancer	1.5e-05	2.77e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—ABCB1—esophageal cancer	1.5e-05	2.76e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—EP300—esophageal cancer	1.5e-05	2.75e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—EGFR—esophageal cancer	1.49e-05	2.73e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—MYC—esophageal cancer	1.49e-05	2.73e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—MYC—esophageal cancer	1.48e-05	2.72e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—EP300—esophageal cancer	1.47e-05	2.71e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—EP300—esophageal cancer	1.47e-05	2.7e-05	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.47e-05	2.7e-05	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—PIK3CA—esophageal cancer	1.47e-05	2.7e-05	CbGpPWpGaD
Asenapine—ADRA2C—Metabolism—PIK3CA—esophageal cancer	1.46e-05	2.68e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—CCND1—esophageal cancer	1.46e-05	2.68e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—EGFR—esophageal cancer	1.45e-05	2.67e-05	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—PIK3CA—esophageal cancer	1.45e-05	2.66e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—EGFR—esophageal cancer	1.45e-05	2.66e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—EP300—esophageal cancer	1.44e-05	2.65e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—MYC—esophageal cancer	1.44e-05	2.64e-05	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—TP53—esophageal cancer	1.42e-05	2.61e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—CDKN1A—esophageal cancer	1.41e-05	2.59e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—EGFR—esophageal cancer	1.41e-05	2.59e-05	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—TP53—esophageal cancer	1.4e-05	2.57e-05	CbGpPWpGaD
Asenapine—CYP2D6—Metabolism—NOS3—esophageal cancer	1.37e-05	2.52e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—EP300—esophageal cancer	1.34e-05	2.46e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—PIK3CA—esophageal cancer	1.32e-05	2.42e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—PIK3CA—esophageal cancer	1.31e-05	2.4e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—MYC—esophageal cancer	1.3e-05	2.4e-05	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—CREBBP—esophageal cancer	1.3e-05	2.39e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—PIK3CA—esophageal cancer	1.29e-05	2.37e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—MYC—esophageal cancer	1.28e-05	2.36e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—MYC—esophageal cancer	1.28e-05	2.36e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—EGFR—esophageal cancer	1.28e-05	2.35e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—TP53—esophageal cancer	1.28e-05	2.35e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—TP53—esophageal cancer	1.26e-05	2.32e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—PIK3CA—esophageal cancer	1.26e-05	2.32e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—MYC—esophageal cancer	1.26e-05	2.31e-05	CbGpPWpGaD
Asenapine—CYP2D6—Metabolism—PTGS2—esophageal cancer	1.26e-05	2.31e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—EGFR—esophageal cancer	1.26e-05	2.31e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—PIK3CA—esophageal cancer	1.25e-05	2.31e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—EGFR—esophageal cancer	1.25e-05	2.3e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—TP53—esophageal cancer	1.25e-05	2.29e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—EGFR—esophageal cancer	1.23e-05	2.26e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—PIK3CA—esophageal cancer	1.22e-05	2.24e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—TP53—esophageal cancer	1.22e-05	2.24e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—TP53—esophageal cancer	1.21e-05	2.23e-05	CbGpPWpGaD
Asenapine—ADRA2A—Metabolism—PIK3CA—esophageal cancer	1.19e-05	2.18e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—TP53—esophageal cancer	1.18e-05	2.17e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—MYC—esophageal cancer	1.17e-05	2.15e-05	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—NOS3—esophageal cancer	1.16e-05	2.14e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—EGFR—esophageal cancer	1.14e-05	2.1e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—PIK3CA—esophageal cancer	1.11e-05	2.04e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—PIK3CA—esophageal cancer	1.09e-05	2e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—PIK3CA—esophageal cancer	1.09e-05	2e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—TP53—esophageal cancer	1.07e-05	1.97e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—PIK3CA—esophageal cancer	1.07e-05	1.96e-05	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—PTGS2—esophageal cancer	1.06e-05	1.96e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—TP53—esophageal cancer	1.05e-05	1.94e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—TP53—esophageal cancer	1.05e-05	1.93e-05	CbGpPWpGaD
Asenapine—CYP2D6—Metabolism—EP300—esophageal cancer	1.04e-05	1.92e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—TP53—esophageal cancer	1.03e-05	1.9e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—CREBBP—esophageal cancer	1e-05	1.84e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—PIK3CA—esophageal cancer	9.91e-06	1.82e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—TP53—esophageal cancer	9.59e-06	1.76e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—NOS3—esophageal cancer	8.97e-06	1.65e-05	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—EP300—esophageal cancer	8.84e-06	1.63e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—PTGS2—esophageal cancer	8.21e-06	1.51e-05	CbGpPWpGaD
Asenapine—CYP2D6—Metabolism—PIK3CA—esophageal cancer	7.72e-06	1.42e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—EP300—esophageal cancer	6.83e-06	1.26e-05	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—PIK3CA—esophageal cancer	6.54e-06	1.2e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—PIK3CA—esophageal cancer	5.05e-06	9.29e-06	CbGpPWpGaD
